1.5.2 The Drug Development Pipeline: From Molecule to Market

A new chemical entity does not become a marketed medicine overnight; it passes through a linear, highly regulated pipeline in which each stage acts as a...

A new chemical entity does not become a marketed medicine overnight; it passes through a linear, highly regulated pipeline in which each stage acts as a filter, eliminating candidates that fail on grounds of activity, safety, or manufacturability. Appreciating this pipeline in its entirety helps a researcher understand why a particular preclinical experiment is being requested and what regulatory purpose it ultimately serves.

Step 1 — Target Identification

The biological macromolecule whose modulation is expected to produce a therapeutic effect is identified and validated, typically using genomic, proteomic, and bioinformatic approaches (see Phase 2).

Step 2 — Hit Discovery

Compound libraries are screened against the validated target to identify 'hits' — molecules showing measurable activity, most commonly via high-throughput in-vitro screening.

Step 3 — Lead Optimisation

Hits are chemically modified to improve potency, selectivity, and drug-likeness, guided by structure-activity relationship (SAR) analysis, yielding one or more 'lead' compounds.

Step 4 — Preclinical Studies (In-vitro and In-vivo)

Lead compounds undergo comprehensive in-vitro pharmacological screening and in-vivo animal testing, including efficacy, pharmacokinetic, and toxicological evaluation (Phases 3–5 of this text).

Step 5 — IND Filing

An Investigational New Drug application, compiling all preclinical pharmacology, toxicology, and manufacturing data, is submitted to the relevant regulatory authority to obtain permission for first-in-human dosing.

Step 6 — Phase I–III Clinical Trials

The candidate is tested in progressively larger human populations: Phase I for safety and tolerability, Phase II for preliminary efficacy, and Phase III for confirmatory efficacy against comparators.

Step 7 — NDA/ANDA Submission

A New Drug Application (or, for generics, an Abbreviated New Drug Application) compiling the full clinical dossier is submitted for marketing authorisation.

Step 8 — Post-market Pharmacovigilance

Following approval, the drug is monitored in the general population for rare or long-latency adverse effects through structured pharmacovigilance programmes.

Note

The attrition rate across this pipeline is severe: industry-wide estimates suggest that fewer than one in ten thousand synthesised or screened compounds ultimately reaches the market, and the majority of preclinical candidates fail at the toxicology or pharmacokinetic stage rather than for lack of biological activity. This underscores why the methodological rigour described throughout this book — correct assay design, appropriate statistics, and GLP compliance — is not a bureaucratic formality but a scientific necessity.